title: [Shiga toxin producing Escherichia coli infection].
abstract: Shiga toxin producing Escherichia coli(STEC) has been recognized as an emerging food-borne pathogen that causes bloody diarrhea, hemorrhagic colitis and hemolytic uremic syndrome(HUS), especially in developed countries. As the specific therapy for STEC infection has not been developed, currently available medical therapy is inadequate to prevent life-threatening complications. Here are described the possibilities and problems of using and developing therapies such as antibiotics, Synsorb-Pk and humanized anti-Stx monoclonal antibody therapy. In conclusion, the prevention of primary infection is thought to be the best way to prevent the life-threatening complications caused by STEC, and second way is identification as early as possible.
authors.affiliation: Department of Infectious Diseases Research, National Children's Medical Research Center, National Children's Hospital.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nakao
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004926:Escherichia coli / Q000378:metabolism; D004927:Escherichia coli Infections / Q000382:microbiology / Q000628:therapy*; D006801:Humans; D051379:Mice; D017646:Organosilicon Compounds / Q000627:therapeutic use; D022641:Shiga Toxin 2 / Q000096:biosynthesis* / Q000276:immunology; D014312:Trisaccharides / Q000627:therapeutic use
chemical_list: D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D017646:Organosilicon Compounds; C119238:SYNSORB Pk; D022641:Shiga Toxin 2; D014312:Trisaccharides